Cover Image
市場調查報告書

Transgene SA的產品平台分析

Transgene SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224693
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Transgene SA的產品平台分析 Transgene SA - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 45 Pages
簡介

Transgene SA是總公司設於法國的生物製藥企業,正在設計、開發針對癌症和慢性感染疾病的免疫療法治療藥。

本報告提供Transgene SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Transgene SA的基本資料

  • Transgene SA概要
  • 主要資訊
  • 企業資料

Transgene SA:R&D概要

  • 主要的治療範圍

Transgene SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Transgene SA:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Transgene SA:藥物簡介

  • TG-4010
  • pexastimogene devacirepvec
  • TG-1042
  • TG-4001
  • TG-4040
  • Vaccine for Undisclosed Indication
  • MVA-TB
  • TG-1050
  • TG-3003
  • TG-6002

Transgene SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Transgene SA:最新的開發平台資訊

Transgene SA:開發暫停中的計劃

Transgene SA:開發中止的開發中產品

Transgene SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07673CDB

Summary

Global Markets Direct's, 'Transgene SA - Product Pipeline Review - 2015', provides an overview of the Transgene SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Transgene SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Transgene SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Transgene SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Transgene SA's pipeline products

Reasons to buy

  • Evaluate Transgene SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Transgene SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Transgene SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Transgene SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Transgene SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Transgene SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Transgene SA Snapshot
    • Transgene SA Overview
    • Key Information
    • Key Facts
  • Transgene SA - Research and Development Overview
    • Key Therapeutic Areas
  • Transgene SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Transgene SA - Pipeline Products Glance
    • Transgene SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Transgene SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Transgene SA - Drug Profiles
    • TG-4010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pexastimogene devacirepvec
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-1042
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-4001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVA-TB
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-1050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-3003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-6002
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Transgene SA - Pipeline Analysis
    • Transgene SA - Pipeline Products by Target
    • Transgene SA - Pipeline Products by Route of Administration
    • Transgene SA - Pipeline Products by Molecule Type
    • Transgene SA - Pipeline Products by Mechanism of Action
  • Transgene SA - Recent Pipeline Updates
  • Transgene SA - Dormant Projects
  • Transgene SA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • TG-1042
  • Transgene SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Transgene SA, Key Information
  • Transgene SA, Key Facts
  • Transgene SA - Pipeline by Indication, 2015
  • Transgene SA - Pipeline by Stage of Development, 2015
  • Transgene SA - Monotherapy Products in Pipeline, 2015
  • Transgene SA - Partnered Products in Pipeline, 2015
  • Transgene SA - Partnered Products/ Combination Treatment Modalities, 2015
  • Transgene SA - Phase II, 2015
  • Transgene SA - Phase I, 2015
  • Transgene SA - Preclinical, 2015
  • Transgene SA - Pipeline by Target, 2015
  • Transgene SA - Pipeline by Route of Administration, 2015
  • Transgene SA - Pipeline by Molecule Type, 2015
  • Transgene SA - Pipeline Products by Mechanism of Action, 2015
  • Transgene SA - Recent Pipeline Updates, 2015
  • Transgene SA - Dormant Developmental Projects,2015
  • Transgene SA - Discontinued Pipeline Products, 2015
  • Transgene SA, Subsidiaries

List of Figures

  • Transgene SA - Pipeline by Top 10 Indication, 2015
  • Transgene SA - Pipeline by Stage of Development, 2015
  • Transgene SA - Monotherapy Products in Pipeline, 2015
  • Transgene SA - Partnered Products in Pipeline, 2015
  • Transgene SA - Pipeline by Top 10 Target, 2015
  • Transgene SA - Pipeline by Top 10 Route of Administration, 2015
  • Transgene SA - Pipeline by Top 10 Molecule Type, 2015
  • Transgene SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top